Big pharma, Partnering, Pharma

Shionogi enters into a pharma licensing deal for hydrocodone opioid products

Posted on 27 November 2013

Tags: , , ,

Egalet has entered into a definitive collaboration and pharma licensing deal with Shionogi for the development and potential commercialization of multiple oral abuse-deterrent hydrocodone opioid product candidates using Egalet's proprietary technology.

Egalet will receive a $10 million upfront payment from Shionogi.

In the pharma licensing deal, Shionogi has agreed to purchase up to approximately $15 million in common stock in a private placement to close concurrently with Egalet's recently filed initial public offering.

Egalet is eligible to receive milestone payments upon development and approval of products, which may exceed $300 million if multiple products are approved.

Shionogi will fund all costs associated with the development of these products.

Shionogi will also have exclusive global rights to commercialize the resulting products.

If any products developed under the collaboration are approved for marketing, Egalet is eligible to receive tiered royalties, ranging from the mid-single digits to the low double digits based on the net sales of such products.

As well as sales-based milestone payments that could exceed $100 million based on the attainment of specified sales thresholds.

Read the full article at Reuters (link no longer available)

For further deal information visit Current Agreements (subscription required)

 

Related

Report: Partnering Deals and Alliances with Shionogi

Report: Hepatitis Partnering

Browse: Complete Current Partnering report catalog

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply